In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Justin A. Clark; Brandon Kulengowski; David S. Burgess

doi:10.1016/j.ijantimicag.2020.106178

In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Justin A. Clark, Brandon Kulengowski, David S. Burgess

Pharmacy Practice and Science

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66–0.87]; however, the MIC₉₀ observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.

Original language	English
Article number	106178
Journal	International Journal of Antimicrobial Agents
Volume	56
Issue number	6
DOIs	https://doi.org/10.1016/j.ijantimicag.2020.106178
State	Published - Dec 2020

Bibliographical note

Publisher Copyright:
© 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy

Keywords

Antimicrobial susceptibility testing
CRE
Carbapenem-resistant Enterobacteriaceae
Eravacycline
Tigecycline

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ijantimicag.2020.106178

Cite this

@article{7715f8eaca684843934f003c106b8343,

title = "In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae",

abstract = "Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66–0.87]; however, the MIC90 observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.",

keywords = "Antimicrobial susceptibility testing, CRE, Carbapenem-resistant Enterobacteriaceae, Eravacycline, Tigecycline",

author = "Clark, {Justin A.} and Brandon Kulengowski and Burgess, {David S.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd and International Society of Antimicrobial Chemotherapy",

year = "2020",

month = dec,

doi = "10.1016/j.ijantimicag.2020.106178",

language = "English",

volume = "56",

number = "6",

}

TY - JOUR

T1 - In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

AU - Clark, Justin A.

AU - Kulengowski, Brandon

AU - Burgess, David S.

PY - 2020/12

Y1 - 2020/12

N2 - Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66–0.87]; however, the MIC90 observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.

AB - Eravacycline has been shown to have broad-spectrum activity against Gram-negative bacteria, including carbapenem-resistant Enterobacteriaceae (CRE). We compared the activity of eravacycline with that of tigecycline in CRE isolates cultured from patients at an academic medical centre. Eravacycline was more potent than tigecycline [mean minimum inhibitory concentration (MIC) ratio = 0.76, 95% confidence interval 0.66–0.87]; however, the MIC90 observed for eravacycline was higher than previously reported at 4 μg/mL. Future studies are necessary to elucidate the mechanism driving this difference.

KW - Antimicrobial susceptibility testing

KW - CRE

KW - Carbapenem-resistant Enterobacteriaceae

KW - Eravacycline

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=85092011732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092011732&partnerID=8YFLogxK

U2 - 10.1016/j.ijantimicag.2020.106178

DO - 10.1016/j.ijantimicag.2020.106178

M3 - Article

C2 - 32980393

AN - SCOPUS:85092011732

SN - 0924-8579

VL - 56

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

IS - 6

M1 - 106178

ER -

In vitro activity of eravacycline compared with tigecycline against carbapenem-resistant Enterobacteriaceae

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this